Is MRD testing ready for “prime time”?

Submitted by blackswan on Fri, 07/15/2016 - 01:17

The answer is a definite yes and no! Yes, it is now a priority to test for minimal residual disease (MRD) in myeloma clinical trials. However, no, MRD testing is not yet recommended in routine clinical practice.  But I’m pleased to report that we are getting there.

Black Swan Research Initiative® Update

Submitted by blackswan on Thu, 07/23/2015 - 22:12

The Black Swan Research Initiative® (BSRI) is on the brink of several key steps forward, I am happy to report.  Great progress has already been made.

Bringing Next Generation Flow (NGF) Cytometry to Japan

Submitted by Dr. Brian GM Durie on Thu, 03/12/2015 - 12:30

On Saturday and Sunday, the IMF was honored to chair a workshop in Tokyo, Japan, which introduced Next Generation Flow Cytometry to more than 160 researchers and technicians eager to learn about this super-sensitive automated new myeloma measuring method.